Maladie de Fabry (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Maladie de Fabry" in French language version.

refsWebsite

Global rank French rank

3wiley.com

222^nd place

129^th place

2annals.org

low place

1,894^th place

2nih.gov

4^th place

12^th place

1whonamedit.com

2,888^th place

2,078^th place

1thelancet.com

2,393^rd place

506^th place

1ama-assn.org

3,257^th place

1,028^th place

1ajhg.org

low place

1oup.com

485^th place

416^th place

1springerlink.com

2,569^th place

766^th place

1therapeutique-dermatologique.org

low place

1,400^th place

1clinicalpain.com

low place

1nature.com

234^th place

147^th place

1nejm.org

2,374^th place

298^th place

1geneticsinmedicine.org

low place

ajhg.org

(en) Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening, Am J Hum Genet, 2006;79: 31-40

ama-assn.org

jama.ama-assn.org

(en) Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders, JAMA, 1999;281:249-54

annals.org

(en) Clarke JTR, Fabry Disease, Ann Intern Med, 2007;146;425-433
(en) Agalsidase-Beta therapy for advanced fabry disease, Maryam Banikazemi, Jan Bultas, Stephen Waldek, William R. Wilcox, Chester B. Whitley, Marie McDonald, Richard Finkel, Seymour Packman, Daniel G. Bichet, David G. Warnock, Robert J. Desnick, Ann Intern Med, 2007;146;77-86

clinicalpain.com

(en) Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A, Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy: a retrospective analysis from the Fabry Outcome Survey, Clin J Pain, 2007;23:535-542

geneticsinmedicine.org

(en) Eng CM, Germain DP, Banikazemi M et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement, Genet Med, 2006;8:539-548

nature.com

(en) Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM, Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta, Kidney Int, 2004;66:1589-1595

nejm.org

Germain DP, Hughes DA, Nicholls K et al. Treatment of Fabry’s disease with the pharmacologic chaperone Migalastat, N Engl J Med, 2016; 375:545-555

nih.gov

ncbi.nlm.nih.gov

(en) Young E, Mills K, Morris P et al. Is globotriaosylceramide a useful biomarker in Fabry disease?, Acta Paediatr Suppl, 2005;94:51-54
(en) Banikazemi M, Ullman T, Desnick RJ,Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy, Mol Genet Metab, 2005;85:255-259

oup.com

academic.oup.com

Pieroni M, Namdar M, Olivotto I, Desnick RJ, Anderson–Fabry disease management: role of the cardiologist, European Heart Journal, 2024;45:1395–1409

springerlink.com

(en) Gold KF, Pastores GM, Botteman MF et al. Quality of life of patients with Fabry disease, Qual Life Res, 2002;11:317-327

thelancet.com

(en) Zarate YA, Hopkin RJ, Fabry's disease, Lancet, 2008;372:1427-1435

therapeutique-dermatologique.org

Lemarchand Venencie F. Rybojad M., « Maladie de Fabry », sur www.therapeutique-dermatologique.org, février 2005 (consulté le 20 juillet 2012)

whonamedit.com

(en) Who Name it? Also known as

wiley.com

www3.interscience.wiley.com

(en) Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A, Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre, Clin Experiment Ophthalmol, 2005;33:164-168
(en) Hegemann S, Hajioff D, Conti G et al. Hearing loss in Fabry disease: data from the Fabry Outcome Survey, Eur J Clin Invest, 2006;36: 654-662

onlinelibrary.wiley.com

Reisin R, Perrin A, García-Pavía P. Time delays in the diagnosis and treatment of Fabry disease, Int J Clin Pract, 2017;71:1–8